BackgroundOpioid use disorder (OUD) is associated with persistent drug use, high relapse rates, and significant morbidity, mortality, and psychosocial harm. While Long-Acting Injectable Buprenorphine (LAIB), marketed as Buvidal, offers improved pharmacological management over traditional opioid substitution therapy (OST), the mental clarity provided by LAIB often surfaces unresolved trauma and mental health needs. Integrating trauma-informed psychological care alongside pharmacological intervention is increasingly recognized as critical to optimize recovery outcomes for individuals with co-occurring psychiatric co-morbidities and substance use disorder.ObjectiveThis evaluation aimed to explore client experience of the Buvidal Psychological Support Service, a tiered trauma-informed psychological service, piloted to support individuals with OUD receiving LAIB in Wales, UK.MethodsQualitative data were derived from nine semi-structured interviews with BPSS service users, exploring their experiences, perceived impacts, and recovery journeys through reflexive thematic analysis.ResultsFindings indicated the transition to LAIB was often transformative but exposed trauma and emotional difficulties previously masked by substance use, making the availability of timely psychological support critical for maintaining abstinence and wellbeing. Clients valued the BPSS’s rapid access, continuity, person-centered care and non-judgmental ethos, reporting enhanced agency, emotional regulation, and social reintegration. Relapse prevention was strongly linked to psychological support alongside pharmacological treatment.ConclusionThe findings suggest that participants experienced BPSS as a valuable adjunct to LAIB, particularly where increased mental clarity brought trauma-related and emotional difficulties into focus. The pilot highlights the potential value of integrating trauma-informed psychological support within LAIB pathways, while further evaluation is needed to assess transferability and longer-term outcomes.
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
Hello there and welcome to a new week. STAT reporter Andrew Joseph here in London filling in for Mr. Pharmalot for the day. Before we get to the headlines, an extra dose of encouragement to check out all the great pieces that STAT has to offer today, from Reed Jobs opining on the NIH budget to our new trust-in-science reporter Nick Florko outlining his own experience grappling with, as he puts it, “how frustrating it is to realize that modern medicine does not have all the answers.” Now to those headlines. …
Novo Nordisk is seeking to assure investors that it can regain its momentum in the coming years, outlining plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines, building off what’s occurring with its obesity treatments, STAT shares. At the company’s capital markets day in London, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and deliver revenue growth on par with other major pharma firms. He also presented a strategy that involved investing more in disease areas outside diabetes and obesity and said the company “will be more active within business development,” an acknowledgment of investors’ concerns that Novo was too reliant on its landmark GLP-1 drugs and needed to develop other products.
Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD, STAT writes. In a randomized Phase 1 study, the company’s new drug, called ALKS 7290, was well tolerated and showed a signal of efficacy. Participants in the study started with a median score of 39 on a diagnostic known as the Adult ADHD Investigator Symptom Rating Scale, indicating that they had moderate to severe symptoms. After two weeks, those taking a high dose of 50 milligrams of ALKS 7290 experienced a 19-point reduction on the scale, indicating that their symptoms had become mild.
A comparative study of traditional Chinese mind-body therapies on sleep quality, mental health, and quality of life in patients with sleep disorders: a network meta-analysis based on randomized controlled trials
BackgroundSleep disorders are a common clinical condition characterized primarily by difficulty falling asleep, trouble maintaining sleep, and impaired daytime functioning, with a high prevalence among adults. This condition can lead to a persistent decline in sleep quality, trigger mental health issues such as anxiety and depression, and ultimately reduce overall quality of life. Traditional Chinese mind-body exercise therapies are considered potentially effective non-pharmacological interventions due to their low risk, high accessibility, and dual mind-body regulation effects. However, the relative efficacy of different exercise therapies on sleep quality, mental health, and quality of life in patients with sleep disorders remains unclear. This study employed a web-based meta-analysis to systematically evaluate the effects of three interventions—Tai Chi, Baduanjin, and Tai Chi combined with transcranial magnetic stimulation—on three outcome measures and to rank their efficacy, aiming to provide evidence-based support for clinical decision-making.MethodsThis study conducted a systematic search of the PubMed, Embase, Web of Science, Cochrane, EBSCO, and CNKI databases and included 18 randomized controlled trials that met the inclusion criteria. Outcome measures included sleep quality, mental health, and quality of life. A network meta-analysis using a random-effects model was performed to calculate standardized mean differences and 95% confidence intervals, and the cumulative ranking probability curve area was used to rank the efficacy of the interventions.ResultThis study included a total of 18 randomized controlled trials. Regarding sleep quality, TCCWTMS yielded the best results (SMD = −1.15, 95% CI [−2.07, −0.22]). Regarding mental health, only the Tai Chi intervention achieved statistical significance (SMD = 0.64, 95% CI [0.07, 1.21], P = 0.03); although Baduanjin ranked first in the SUCRA ranking (92.6%), pairwise comparisons did not reach statistical significance (P = 0.07). Regarding quality of life, both Tai Chi (SMD = -0.47, 95% CI [-0.71, -0.24], P < 0.0001) and Baduanjin (SMD = -0.57, 95% CI [-0.91, -0.23], P = 0.001) were significantly effective. There were significant heterogeneous differences in the efficacy of the three interventions across different outcome measures.ConclusionThis study indicates that the TCCWTMS is the most effective intervention for improving sleep quality in patients with sleep disorders. Regarding quality of life, both Baduanjin and Tai Chi demonstrated significant effects, with Baduanjin showing superior efficacy. Regarding mental health, the current evidence is insufficient to determine the optimal intervention strategy. There are significant differences in the efficacy of the three interventions across various outcome measures; clinical decisions can be made by selecting the appropriate intervention based on the patient’s score needs.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261415202, identifier CRD420261415202.
Efficacy of mindfulness-based interventions for children and adolescents with attention deficit hyperactivity disorder: a systematic review and meta-analysis
Background and objectiveAttention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. Although mindfulness-based interventions (MBIs) have been proposed as promising non-pharmacological treatments, evidence regarding their efficacy in children and adolescents with ADHD remains inconsistent.MethodsA systematic search of PubMed, Embase, the Cochrane Library, Scopus, and Web of Science was conducted up to December 31, 2025, supplemented by manual screening of reference lists. Eligible studies were randomized controlled trials (RCTs) in which mindfulness-based intervention was the primary treatment for children or adolescents with ADHD, even alongside other therapies. Study selection followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk of bias was assessed using the Cochrane RoB 1.0 tool. Meta-analyses employed random-effects or fixed-effects models based on heterogeneity.ResultsFourteen randomized controlled trials were included in the meta-analysis. The results demonstrated that MBIs significantly alleviated core ADHD symptoms in children (standardized mean difference (SMD) = -1.30; 95% confidence interval (95% CI) [-2.14, -0.45]; p = 0.003). However, the heterogeneity was considerably high (I² = 91%), and publication bias could not be excluded (as suggested by funnel plot/Egger’s test, if available). Regarding neurocognitive functions, MBIs showed potential benefits in improving attention network function (SMD = 0.44; 95% CI [0.01, 0.87]; p = 0.04; I² = 88%) and executive function (SMD = 0.45; 95% CI [0.02, 0.88]; p = 0.04; I² = 84%), though the high heterogeneity (I² > 75%) and possible publication bias warrant cautious interpretation. No significant effects were observed on emotional problems, social problems, externalizing behavioral problems (including oppositional defiant, disruptive, and aggressive behaviors), or mindfulness skills.ConclusionsThis systematic review suggests that MBIs may improve core ADHD symptoms and neurocognitive functions (including attention and executive functions) in children and adolescents. Yet, effects on emotional health, social relationships, externalizing behaviors, and mindfulness skills remain inconclusive. While suggesting that MBIs hold promise as a potential adjunctive intervention alongside standard treatments, significant heterogeneity underscores the need for further high-quality research to confirm these therapeutic benefits.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251171407, identifier CRD420251171407.
Therapist Skepticism and Adaptation to Teletherapy Under Enforced Uptake, With Theoretical Considerations for AI-Mediated Care: Qualitative Study
<strong>Background:</strong> Mental health care is undergoing rapid digital transformation, with continued development and implementation of digitally delivered interventions. Despite growing evidence for digital mental health interventions, implementation in routine practice has often lagged technological advances. Although teletherapy became more widely accepted during the COVID-19 pandemic, little is known about the psychological processes through which clinicians adapt to disruptive changes in treatment delivery when required to work within a novel medium. <strong>Objective:</strong> This study explored how therapists who had not previously adopted teletherapy interpreted and adapted to its enforced uptake during the COVID-19 pandemic, with particular attention to changes in expectations, perceptions of the therapeutic alliance, and professional practice. <strong>Methods:</strong> Six UK-based accredited clinical psychologists, none of whom had previously practiced video-based teletherapy, participated in semistructured interviews conducted between May and July 2021, following the rapid shift toward remote delivery. Data were analyzed using reflexive thematic analysis to explore therapists’ experiences of adaptation, belief revision, and therapeutic interactions. <strong>Results:</strong> We identified the following four themes: (1) revision of anticipatory beliefs, (2) context-medium differentiation, (3) medium affordances, and (4) relational viability and selective integration. Therapists began practicing teletherapy with concerns about accessibility, safety, therapeutic techniques, and relational quality. With sustained practice, clinicians revised many of their assumptions. Therapists also distinguished difficulties associated with implementation contexts from perceived properties of teletherapy itself. They described adapting clinical procedures and techniques, recognizing both constraints and affordances of the medium, and developing more differentiated views of when teletherapy was appropriate. Clinicians generally found teletherapy to be an acceptable therapeutic medium, but not equivalent to in-person practice. <strong>Conclusions:</strong> Adapting to teletherapy involved more than accepting a new tool. It required therapists to reconsider assumptions about therapeutic interaction, safety, and conditions needed to sustain an effective therapeutic relationship. The findings suggest an experience-based professional adaptation process in which initial assumptions became differentiated through sustained use. While these findings support teletherapy uptake specifically, they may also inform how clinicians evaluate other digital mental health technologies, while recognizing that changes to the communication medium are not equivalent to changes in the therapeutic process or agent.
An Evidence-Based AI Virtual Assistant for Young People With Attention Deficit Hyperactivity Disorder: Co-Design and Prototype Development
<strong>Background:</strong> Though attention deficit hyperactivity disorder (ADHD) is thought to be the most prevalent neurodevelopmental disorder in young people worldwide, there are inequalities in access to psychoeducation and health care support. One way to improve access, potentially increase engagement, reduce health care inequalities, and enhance care is by co-developing digital responsive interventions. These have the potential to support long-term condition management and to act as an adjunct to usual care. Virtual assistants that use large language models can provide information in response to questions and learn to tailor communication to suit an individual user’s needs. This can be especially valuable for people with ADHD who often struggle to regulate attention and can experience communication challenges. Involving people with lived experience in the co-design process is crucial for the development of effective digital interventions. Therefore, this article explores the views and preferences of young people with ADHD and their supporters from the United Kingdom who collaborated with researchers to co-design a prototype chatbot. <strong>Objective:</strong> This study aimed to co-develop an evidence-based chatbot prototype, intended to help young people with ADHD thrive through improved access to health care information, psychoeducation, and self-management strategies. <strong>Methods:</strong> An interdisciplinary team was established, including researchers, software developers, clinicians, and lived experience collaborators. Research advisory and working groups were set up in ways that facilitated flexible involvement. Following the person-based approach, guiding principles were established, and workshops were held with young people with ADHD and supporters of young people with ADHD to co-develop an early prototype. Feedback was sought via think-aloud interviews with lived experience collaborators. <strong>Results:</strong> In total, 9 experts by lived experience and 3 health care professionals chose to engage in workshops, and this feedback informed the development of a SmartADHD chatbot prototype. An off-the-shelf chatbot (GPT-4o hosted on Convai) was trained using resources from the National Health Service (NHS). Overall, 6 experts by lived experience engaged with think-aloud interviews, providing feedback on the prototype conversational flow and feel, the avatar, the text-to-speech, the chatbox feature, and the content of the messages. Seven recommendations are made for future development, which will inform the SmartADHD program of work. <strong>Conclusions:</strong> These findings provide rich data on the preferences of people with ADHD. Specific recommendations for a chatbot for young adults with ADHD have not been investigated before with young people, making this study a novel contribution to the field. These findings provide an excellent foundation for chatbot development for this group and may be relevant for those developing digital tools for people with ADHD across the lifespan and other neurodevelopmental conditions. Further work is required to elucidate the views of health care professionals and identify the limits of the technology before subsequent evaluation. <strong>Trial Registration:</strong>
Remotely Supervised, Home-Based Transcranial Direct Current Stimulation for Major Depressive Disorder: Systematic Review and Meta-Analysis
Background: Major depressive disorder affects over 280 million people worldwide, and access to effective treatment remains limited. Transcranial direct current stimulation (tDCS) is a noninvasive option, and portable devices now allow for home-based delivery under varying degrees of remote supervision. Objective: This study aimed to systematically review and meta-analyze the efficacy, safety, feasibility, and acceptability of home-based and remotely supervised tDCS for depressive disorders. Methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 and PRISMA-S (Preferred Reporting Items for Systematic Reviews and Meta-Analyses literature search extension) guidelines, we searched MEDLINE, Embase, Web of Science, the Cochrane databases, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to July 2025, with backward and forward citation searching. Two reviewers independently screened records, extracted data, and assessed risk of bias (version 2 of the Cochrane risk-of-bias tool for randomized trials, Newcastle-Ottawa Scale for observational studies, and Critical Appraisal Skills Programme for qualitative studies) and certainty of evidence (Grading of Recommendations Assessment, Development, and Evaluation; GRADE). Results: This review included 12 distinct studies (16 reports), of which 6 (50%) were randomized sham-controlled trials forming the meta-analytic pool. Active home-based tDCS produced a small, statistically significant improvement over sham (pooled Hedges =0.36, 95% CI 0.06-0.66; =.03; =34.3%). The effect was not robust to removal of the single largest positive trial (omitting the one study from 2025: =0.39, 95% CI −0.12 to 0.91), and trial-level results were mixed: the 2 largest trials (one unsupervised [n=210] and one self-administered [n=141]) were negative on their primary depression outcomes, whereas the largest real-time supervised trial (n=174) was positive (between-group 95% CI 0.51‐4.01; =.01). This estimate was concordant in direction with an independent peer-reviewed meta-analysis of overlapping trials, which reported a pooled Montgomery-Åsberg Depression Rating Scale reduction (weighted mean difference −2.74, 95% CI −4.19 to −1.29) and Hamilton Depression Rating Scale reduction (weighted mean difference −2.24, 95% CI −4.16 to −1.49), attenuating to nonsignificance (>.05) in major depressive disorder without comorbid cognitive impairment. The pooled effect fell at or near the minimal clinically important difference. GRADE certainty was moderate. Adverse events were predominantly mild: one pilot study was terminated early for skin lesions, and one nonfatal suicide attempt occurred in an unsupervised trial. Conclusions: Home-based and remotely supervised tDCS produces a small, statistically significant but clinically modest antidepressant effect that is sensitive to the inclusion of the largest positive trial, with the 2 largest trials being negative. The available controlled evidence does not establish supervision intensity as a determinant of efficacy. Current data are insufficient to recommend routine clinical adoption; adequately powered trials with standardized supervision and longer follow-up are needed. Trial Registration: PROSPERO registration number CRD420251109275; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251109275
INTEGRATING EXPOSURE AND RESPONSE PREVENTION AND HABIT REVERSAL TECHNIQUES TO TREAT A TOURETTIC SUBTYPE OF OBSESSIVE-COMPULSIVE DISORDER (TOURETTIC OCD).
Conditions: Obsessive – Compulsive Disorder; Tic Disorder, Chronic Motor or Vocal; Tic Disorders; Tic Disorder, Combined Vocal and Multiple Motor; Tourette Disease; Tourette Disorder; Tourettes Syndrome; Gilles de la Tourette Syndrome
Interventions: Behavioral: Exposure and Response Prevention (ERP); Behavioral: Habit Reversal Training (HbRT; Behavioral: Psychoeducation and Supportive Intervention
Sponsors: University College London Hospitals
Recruiting
Interventions: Behavioral: Exposure and Response Prevention (ERP); Behavioral: Habit Reversal Training (HbRT; Behavioral: Psychoeducation and Supportive Intervention
Sponsors: University College London Hospitals
Recruiting
Effects of visual art therapy on depressive symptoms in adults: a systematic review and meta-analysis
ObjectiveTo systematically evaluate the intervention effects of visual art therapy on depressive symptoms in adults, and to examine its impact on anxiety symptoms.MethodsA systematic search was conducted in databases including CNKI, WanFang Data, VIP, Chinese Biomedical Literature Database (CBM), PubMed, Web of Science, Cochrane Library, and Embase from inception to March 2026. Randomized controlled trials were included in which visual art therapy was used to intervene in depressive symptoms among adults (≥18 years).Meta-analysis was performed using Stata 18.0 software.The primary outcome was depressive symptoms, measured by scales such as the BDI, GDS, HADS-D, and SDS, and the secondary outcome was anxiety symptoms, measured by scales such as the BAI, HADS-A, and SAS. Fixed-effect or random-effect models were selected according to the level of heterogeneity, and subgroup analyses were conducted.ResultsA total of 12 randomized controlled trials involving 741 adults were included, with 377 participants in the intervention group and 364 in the control group.The meta-analysis showed that visual art therapy effectively alleviated depressive symptoms (SMD = -0.81, 95% CI: -1.16 to -0.46, P < 0.00001) and anxiety symptoms (SMD = -0.69, 95% CI: -0.90 to -0.48, P < 0.00001) in adults.Subgroup analyses indicated that interventions with a duration of <12 weeks, <12 sessions in total, and a single-session length of ≤60 minutes were associated with larger effect sizes for the improvement of depressive symptoms; improvements in anxiety symptoms were more pronounced in intervention protocols characterized by higher frequency (>12 sessions), shorter overall duration (≤6 weeks), and shorter single-session length (≤60 minutes).ConclusionAs a non-pharmacological intervention, VAT has potential as an adjunctive approach for alleviating depressive and anxiety symptoms in adults.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261371354, identifier CRD420261371354.
Effects of exercise interventions on executive function in autism spectrum disorder: a three-level meta-analytic review
ObjectiveThis study aimed to use a three-level meta-analysis to examine the effects of exercise interventions on executive function (EF) in children and adolescents with autism spectrum disorder (ASD), and to explore the relationship between exercise dose and intervention effects through subgroup analyses.MethodsA systematic search was conducted in Web of Science, PubMed, Embase, and the Cochrane Library from database inception to November 17, 2025. All included studies were randomized controlled trials. A three-level random-effects model was applied to integrate multiple dependent effect sizes. Hedges’ g was used to calculate effect sizes, and negative values indicated improvements in EF following exercise interventions. Study quality was assessed using the PEDro scale, and publication bias was evaluated using Egger’s regression and the trim-and-fill method.ResultsSeventeen studies involving 626 participants were included. Exercise interventions produced a moderate and significant improvement in EF (g = –0.34, p < 0.0001) with low heterogeneity (Q = 50.42, p =0.268). Subgroup analyses showed that only intervention duration significantly moderated the effects, with programs lasting ≥10 weeks yielding the greatest benefits.ConclusionExercise interventions significantly improve EF in children and adolescents with ASD, with the largest effect sizes observed in interventions lasting ≥10 weeks. Further large-scale studies are needed to clarify dose–response relationships and inform optimal exercise prescriptions. This meta-analysis was designed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251236112